Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice

Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease

(2018) Michael S. Rafii et al.   JAMA Neurology

Methods for Measuring Tau Pathology in Transgenic Mouse Models

(2018) Stefanie K. Forest et al.   JOURNAL OF ALZHEIMERS DISEASE

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

(2017) Christina Ising et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cryo-EM structures of tau filaments from Alzheimer’s disease

(2017) Anthony W. P. Fitzpatrick et al.   NATURE

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

(2017) Jerry R. Mendell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice

(2016) Wencheng Liu et al.   JOURNAL OF NEUROSCIENCE

Detecting tau in serum of transgenic animal models after tau immunotherapy treatment

(2016) Cristina d'Abramo et al.   NEUROBIOLOGY OF AGING

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

(2016) Matthew R. Brier et al.   Science Translational Medicine

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement

(2016) Seung-Hye Lee et al.   Cell Reports

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain

(2015) Shuko Takeda et al.   Nature Communications

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

(2015) Sethu Sankaranarayanan et al.   PLoS One

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies

(2015) Cristina d’Abramo et al.   PLoS One

A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease

(2014) Michael S. Rafii et al.   Alzheimers & Dementia

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

(2014) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside

(2014) Valerie Ferreira et al.   Frontiers in Immunology

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity

(2013) Cristina d’Abramo et al.   PLoS One

scFv Antibody: Principles and Clinical Application

(2012) Zuhaida Asra Ahmad et al.   Clinical & Developmental Immunology

Drug Transport across the Blood–Brain Barrier

(2012) William M Pardridge   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Targeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease

(2012) J. L. Furman et al.   JOURNAL OF NEUROSCIENCE

Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models

(2012) Christopher M. Acker et al.   NEUROBIOLOGY OF AGING

Adeno-associated virus (AAV) gene therapy for neurological disease

(2012) Marc S. Weinberg et al.   NEUROPHARMACOLOGY

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

(2011) Peter A LeWitt et al.   LANCET NEUROLOGY

Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal Models

(2011) Kleopatra Rapti et al.   MOLECULAR THERAPY

Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases

(2011) Christopher D. Herzog et al.   Drug Delivery and Translational Research

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice

(2009) Donna Wilcock et al.   CNS & Neurological Disorders-Drug Targets

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

(2009) C. W. Christine et al.   NEUROLOGY

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

(2008) D. Boche et al.   BRAIN

Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Aβ Deposits in APP + PS1 Transgenic Mice

(2008) Niki C Carty et al.   MOLECULAR THERAPY